What is HC Wainwright’s Estimate for IOVA Q1 Earnings?

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) – Research analysts at HC Wainwright issued their Q1 2025 EPS estimates for shares of Iovance Biotherapeutics in a note issued to investors on Friday, February 28th. HC Wainwright analyst J. Pantginis anticipates that the biotechnology company will earn ($0.23) per share for the quarter. HC Wainwright has a “Buy” rating and a $32.00 price objective on the stock. The consensus estimate for Iovance Biotherapeutics’ current full-year earnings is ($1.24) per share. HC Wainwright also issued estimates for Iovance Biotherapeutics’ Q4 2025 earnings at ($0.13) EPS.

Iovance Biotherapeutics (NASDAQ:IOVA) last released its quarterly earnings results on Thursday, February 27th. The biotechnology company reported ($0.26) EPS for the quarter, meeting analysts’ consensus estimates of ($0.26). Iovance Biotherapeutics had a negative return on equity of 58.43% and a negative net margin of 451.25%. The business had revenue of $73.69 million during the quarter, compared to analyst estimates of $72.17 million.

IOVA has been the topic of a number of other reports. The Goldman Sachs Group reduced their price objective on shares of Iovance Biotherapeutics from $22.00 to $19.00 and set a “buy” rating on the stock in a research report on Monday. Chardan Capital lowered their price target on Iovance Biotherapeutics from $34.00 to $30.00 and set a “buy” rating on the stock in a report on Monday. Robert W. Baird dropped their target price on Iovance Biotherapeutics from $24.00 to $20.00 and set an “outperform” rating on the stock in a research report on Friday, February 28th. Truist Financial lowered their target price on Iovance Biotherapeutics from $25.00 to $15.00 and set a “buy” rating on the stock in a research report on Monday. Finally, Piper Sandler cut their price objective on shares of Iovance Biotherapeutics from $7.50 to $6.00 and set a “neutral” rating for the company in a report on Friday, February 28th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $20.25.

Iovance Biotherapeutics Stock Performance

IOVA opened at $3.92 on Monday. The stock’s 50 day moving average price is $6.14 and its 200-day moving average price is $8.50. Iovance Biotherapeutics has a 52-week low of $3.62 and a 52-week high of $17.64. The stock has a market capitalization of $1.19 billion, a PE ratio of -2.63 and a beta of 0.53.

Institutional Trading of Iovance Biotherapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the business. Creative Planning grew its stake in Iovance Biotherapeutics by 2.6% in the 3rd quarter. Creative Planning now owns 73,489 shares of the biotechnology company’s stock worth $690,000 after acquiring an additional 1,896 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Iovance Biotherapeutics by 31.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,978 shares of the biotechnology company’s stock worth $105,000 after buying an additional 2,624 shares in the last quarter. Creative Financial Designs Inc. ADV increased its stake in shares of Iovance Biotherapeutics by 59.3% during the third quarter. Creative Financial Designs Inc. ADV now owns 21,740 shares of the biotechnology company’s stock valued at $204,000 after buying an additional 8,090 shares during the period. Farther Finance Advisors LLC raised its holdings in shares of Iovance Biotherapeutics by 142.3% in the third quarter. Farther Finance Advisors LLC now owns 15,389 shares of the biotechnology company’s stock valued at $145,000 after acquiring an additional 9,037 shares in the last quarter. Finally, Beacon Financial Advisory LLC lifted its stake in Iovance Biotherapeutics by 42.7% in the third quarter. Beacon Financial Advisory LLC now owns 21,120 shares of the biotechnology company’s stock worth $198,000 after acquiring an additional 6,320 shares during the period. 77.03% of the stock is currently owned by institutional investors.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.